tionally active tissue factor activity in rabbit and human subendothelium.
Vessel Segments

METHODS
Blood vessels were obtained from two sources. Some studies used an everted segment of rabbit aorta, whose endothelium has been completely removed by balloon catheter, as previously descnibed)92' In other studies, human umbilical arteries'7 were used. Within five minutes of placental separation, a 15 cm section of umbilical cord was removed and rinsed several times in sterile saline. The umbilical artery was dissected out and, using a blunt needle and syringe, flushed under pressure, with 10 mL ofsaline.
Histologic examination of vessel cross sections showed that virtually all endothelial cells had been removed during these procedures.
The arteries were processed further by one of two methods. Method
I.
The vessels were stored in 0.2 mol/L Tnis, pH 7.4 containing 200 U/mL penicillin and 0.2 mg/mL streptomycin for seven to 14 days and then evented and exposed to air in a manner similar to that used to event rabbit aonta.' 2' The completely de-endothelialized artery was then mounted on the inner rod of the perfusion chamber.' 2' Method 2.
The artery was removed and flushed with saline, as above, and then ballooned by means of a Fogarty arterial embolectomy catheter, size 3 F, which was inserted into the artery, inflated to a width of 4 mm, and withdrawn.
The de-endothelialized vessel was stored, as above, for 24 to 48 hours and, after eversion, used immediately for perfusion experiments. used at a concentration (70 ig/mL) that prolonged the prothrombin time obtained by adding a suspension of purified human brain tissue factor to normal human plasma from I 7 to 58 seconds. A control monoclonal IgG antibody (2.2.9) to human von Willebrand factor (a generous gift of Dr Theodore Zimmerman, La iolla, CA), used at the same concentration, had no effect on the prothrombin time, tested as above.
Perfusion Studies
Subjects
Control subjects were normal hospital personnel.
Three patients with congenital factor VII deficiency were studied. These patients have moderate bleeding disorders, factor VII levels of 2% to 3%, and factor VII antigen levels of 1%, 1.7%, and 50%.32 One patient each with previously described" congenital deficiencies of factor V (4% factor V) and factor X (<1%) were also studied. .'I ,.
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__i . were used for the perfusion study (Table  1) . Tissue factor activity on subendothelium was also demonstrated using a stirred (nonlaminan) flow system in which coagulation proteins were exposed to vessel segments mounted on a stir ban in the cuvette of an aggregometen (Fig   2) . In this system, the procoagulant properties (recalcification time) of the subendothelial surface of the human vessel were specifically inhibited by an antibody to human tissue factor. More specifically, the capacity of the surface to activate 'H-factor X was entirely dependent on factor VIla (Fig 5) and was inhibited by the antitissue factor antibody. only.
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